Erasca Investor Presentation Deck
January 2024, 41 slides
  1. Erasca
  2. Related Decks
  3. Investor Presentation Decks
on a journey to erase cancer | Erasca
disclaimer forward looking statements market data | Erasca
our name is our mission to erase cancer | Erasca
sab includes world leading experts in the ras pathway | Erasca
deep modality agnostic ras pathway focused pipeline | Erasca
our singular focus is on the ras pathway | Erasca
clinical development plan generates multiple ways to win for patients | Erasca
pan could address unmet needs in over patients in the us and | Erasca
is a potent and selective inhibitor of and with sub potency and most advanced pan in development | Erasca
| Erasca
has been dosed in more than patients to date establishing its safety tolerability and preliminary in multiple indications deb | Erasca
potential for rapid market entry and multiple ways to benefit patients with ras driven tumors | Erasca
| Erasca
| Erasca
| Erasca
seacraft has the potential to be first in class targeted treatment for melanoma | Erasca
melanoma case study partial response with | Erasca
compelling reproducible clinical efficacy across studies and doses melanoma patients | Erasca
demonstrated a favorable manageable safety profile | Erasca
dose optimization designed to enhance combination benefit risk profile to increase probability of regulatory success in light of project | Erasca
pivotal phase and phase trial designs capitalize on promising efficacy signals and support potential successful registration in multiple indications setae dor secondary | Erasca
eras could address unmet needs in patients annually in the us and | Erasca
we believe eras is the most potent inhibitor in development with a uniquely longer target residence time | Erasca
eras is a potential best in class treatment for patients with | Erasca
eras in | Erasca
meaningful activity in supports initial focus on and dose expansion of this patient segment naive | Erasca
eras was generally well tolerated with primarily grade or observed | Erasca
eras could address high unmet need in patients in us and | Erasca
poor activity of legacy in due to minimal activity against specific alterations and poor penetration | Erasca
eras penetrant designed to overcome the limitations of current treatments | Erasca
eras a potent inhibitor with a over fold higher than approved inhibitors was specifically designed to inhibit in actin | Erasca
eras significantly extends survival at clinically relevant exposures in an amplified and model treatment day | Erasca
dose cohorts | Erasca
anticipated key milestones and clinical trial | Erasca
compelling investment thesis | Erasca
thank you | Erasca
lives at stake annually with ras pathway alterations of unmet needs are blue oceans with no approved targeted therapies | Erasca
potential first in class pan inhibitor day one | Erasca
eras potential best in class inhibitor in a field marked by attrition | Erasca
eras blocked the feedback reactivation observed with or other plus inhibitor combinations | Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
See More
Erasca
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Melanoma
Tumor
Inhibitor
Solid tumor
Clinical trial
Clinical development
Recent decks by Erasca
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
See all presentations by Erasca (4 decks)
Related decks
Alkermes
Investor Day
March 2021
Immatics
Investor Presentation
November 2023
23andMe
Investor Presentation
January 2024
BioAtla
IPO
December 2020
BioNTech
Results
August 2020
BioNTech
Results
May 2021
BioNTech
Results
August 2021
Allarity Therapeutics
Investor Conference
September 2022
Recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Alkermes
Investor Day
March 2021
Immatics
Investor Presentation
November 2023
23andMe
Investor Presentation
January 2024
BioAtla
IPO
December 2020
BioNTech
Results
August 2020
BioNTech
Results
May 2021
BioNTech
Results
August 2021
Allarity Therapeutics
Investor Conference
September 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io